Skip to content
NewsBlazeIN – Lifestyle
Author:
MaxCyte, Inc
MaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing and Expecting to Nearly Double Revenue Base
November 10, 2026
MaxCyte Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue Guidance
November 10, 2026
MaxCyte to Participate in Three Upcoming Investor Conferences
October 28, 2026
MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
October 14, 2026
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
September 23, 2026
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 11, 2026
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
August 19, 2026
MaxCyte Reports Second Quarter 2026 Financial Results
August 12, 2026
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
July 21, 2026
MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026
July 15, 2026